Illumina: China-made MiSeq i100 Series-CN deliveries to exceed 20 units by year-end

Local manufacturing is the real signal here: Illumina is rebuilding its China footprint around production and service proximity, not just product launches, which matters for a market where supply reliability has become a competitive issue. The stated delivery target is small in absolute terms, so the significance lies in proof of execution rather than scale. For China's genomics and clinical sequencing users, the question worth watching is whether local output and service depth keep pace with demand, and whether the quality-parity claim holds as volumes grow.